SHENZHEN, CHINA — Moptim has completed a Series B funding round of nearly RMB 100 million. The financing round was led by China Venture Capital Co., Ltd. (CVC), with follow-on investments from CAS Investment and BV Baidu Ventures.

"Moptim delivers strong technical capabilities across the ophthalmic diagnostic pipeline. Their early international expansion and cost-optimized hardware platform position them well to become a leading global supplier of total eye care solutions." — Representative, China Venture Capital Co., Ltd.

Key Drivers

With complete in-house control over Time-Domain, Spectral-Domain, and Swept-Source OCT technologies, Moptim continues to strengthen its technical edge through embedded AI diagnostics and an expanding global footprint.

The newly raised capital will be strategically allocated to: 

· Advance Core R&D: Elevate high-speed, high-resolution imaging performance and upgrade AI-assisted clinical features.

· Scale Manufacturing: Expand smart manufacturing capacity to ensure supply chain reliability for growing global demand.

· Strengthen Global Support: Build out localized service networks, distribution channels, and clinical training hubs worldwide.

Strategic Outlook 

Moptim is dedicated to developing accessible, high-precision ophthalmic diagnostic equipment. By combining hardware innovation with artificial intelligence, the company continues to provide healthcare professionals worldwide with reliable clinical solutions.